CAMBRIDGE, Mass., Feb. 16, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced the appointment of Chief Executive Officer Marc D. Beer to The Biotechnology Industry Organization's Board of Directors as a member of the Emerging Companies Section Governing Board.
BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services for more than 1,100 members worldwide. As a member of the Board in the Emerging Companies Section, Mr. Beer will utilize his experience bringing companies from development stage through commercialization, and will collaborate to serve the needs of small to medium size BIO member companies, most of whom do not yet have major products approved and on the market.
Marc D. Beer commented, "I'm pleased to re-join the BIO Board of Directors and I look forward to working with some of the top executives in the biotechnology industry as an advocate for emerging companies."
Alan Eisenberg, Executive Vice President of Emerging Companies and Business Development at BIO said, "We are delighted to welcome Marc to the Emerging Companies Section Governing Board of BIO. Marc's expertise in recently conducting a successful IPO in a challenging market environment will surely prove valuable to both the organization and our members."
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders. The Company's lead product, lomitapide, is in Phase III clinical development. Lomitapide is initially being developed to treat patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH. The Company also plans to initiate a clinical program for lomitapide to treat patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtech Now, an online portal and monthly newsletter chronicling "innovations transforming our world."
Editors Note: Photo available upon request of LaVoie Group.
CONTACT: Aegerion Pharmaceuticals, Inc. Corporate Will Lewis, President +1 (908) 704-1300 LaVoie Group, Inc. Investors & Media Amanda Murphy +1 (978) 745-4200 x107 firstname.lastname@example.org